FDA Approves Olaparib for Treatment of Advanced Prostate Cancer - Prostate Cancer Research Centre Report

Wednesday, 20th May 2020

The Prostate Cancer Research Centre reports:

This has been a truly historic week, with two new treatment options receiving FDA approval for men with advanced prostate cancer. Today, olaparib was approved by the FDA for certain metastatic prostate cancers that are not responsive to hormone therapy. Just last Friday, another drug in the class referred to as PARP inhibitors, rucaparib, was also approved.

For men with advanced disease, this is another modern weapon in the fight against advanced prostate cancer, a disease state that in the past had few treatment alternatives. For PCF science, these approvals are an important testament to the value of early foundational work which can bear multiple fruits in the form of new treatments, even many years later. Once again, PCF is proud to have been involved since the beginning, in every stage of the research that lead to this development.

To read the full report on the PCRC website pcf.org, click here